OCSE:NOVO B (Denmark)  
Novo Nordisk A/S logo

Novo Nordisk A/S

kr 879.90 (+2.5%) Nov 29
P/E:
37.03
P/B:
25.28
Market Cap:
kr 1.93T ($ 269.25B)
Enterprise V:
kr 1.92T ($ 267.65B)
Volume:
2.55M
Avg Vol (2M):
1.50M
Also Trade In:
Volume:
2.55M
Market Cap kr:
1.93T
Market Cap $:
269.25B
PE Ratio:
37.03
Avg Vol (2-Month):
1.50M
Enterprise Value kr:
1.92T
Enterprise Value $:
267.65B
PB Ratio:
25.28
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Financials (Next Earnings Date:2023-02-02 Est.)

OCSE:NOVO B's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr) 167,195
EPS (TTM) (kr) 23.18
Beta 0.8
Volatility % 24.11
14-Day RSI 68.31
14-Day ATR (kr) 18.72235
20-Day SMA (kr) 837.185
12-1 Month Momentum % 13.46
52-Week Range (kr) 604.4 - 892.4
Shares Outstanding (Mil) 2,251.72

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Novo Nordisk A/S Filings

Document Form Filing Date
No Filing Data

Novo Nordisk A/S Analysis

Share your research